Gregory Russotti Sells 10,076 Shares of Century Therapeutics (NASDAQ:IPSC) Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 10,076 shares of Century Therapeutics stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $2.55, for a total transaction of $25,693.80. Following the completion of the transaction, the insider directly owned 515,427 shares of the company’s stock, valued at $1,314,338.85. The trade was a 1.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gregory Russotti also recently made the following trade(s):

• On Monday, March 9th, Gregory Russotti sold 479 shares of Century Therapeutics stock. The stock was sold at an average price of $2.54, for a total transaction of $1,216.66.

Century Therapeutics Trading Down 5.8%

Shares of NASDAQ IPSC opened at $2.29 on Wednesday. Century Therapeutics, Inc. has a 12-month low of $0.34 and a 12-month high of $3.04. The firm’s 50-day moving average price is $2.14 and its 200-day moving average price is $1.14. The stock has a market capitalization of $200.15 million, a price-to-earnings ratio of -16.36 and a beta of 1.70.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. On average, equities analysts predict that Century Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IPSC. Prudential Financial Inc. purchased a new stake in shares of Century Therapeutics in the second quarter worth approximately $25,000. Qube Research & Technologies Ltd purchased a new position in Century Therapeutics during the 2nd quarter valued at $38,000. Raymond James Financial Inc. bought a new position in Century Therapeutics in the 2nd quarter valued at $51,000. AQR Capital Management LLC grew its position in Century Therapeutics by 358.9% in the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after acquiring an additional 86,875 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock worth $67,000 after purchasing an additional 34,466 shares during the period. Institutional investors own 50.20% of the company’s stock.

Analysts Set New Price Targets

IPSC has been the subject of a number of recent research reports. Leerink Partners set a $2.00 target price on Century Therapeutics and gave the stock a “market perform” rating in a report on Friday. Piper Sandler increased their price target on Century Therapeutics from $2.00 to $4.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. TD Cowen assumed coverage on Century Therapeutics in a research report on Wednesday, February 25th. They issued a “buy” rating for the company. Zacks Research lowered shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 12th. Finally, Wall Street Zen upgraded shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $3.80.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.